Get the Stockscreener App
0.0584
32.95%
-0.0287
Bio Path Holdings Inc stock is traded at $0.0584, with a volume of 17,676.
It is down -32.95% in the last 24 hours and down -32.95% over the past month.
See More
Previous Close:
$0.0871
Open:
$0.064
24h Volume:
17,676
Relative Volume:
20.53
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.08M
P/E Ratio:
-0.0017
EPS:
-34.43
Net Cash Flow:
$-11.54M
1W Performance:
-32.95%
1M Performance:
-32.95%
6M Performance:
-86.27%
1Y Performance:
-97.18%
1-Day Range:
$0.062
$0.07
1-Week Range:
$0.062
$0.07
52-Week Range:
$0.062
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.064 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.78 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
815.91 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
413.30 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
810.69 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
171.16 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - simplywall.st
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
North American Morning Briefing : Stock Futures Rise as 2026 Trading Year Begins - MarketScreener
Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld MedTech
What analyst consensus implies for Bio Path Holdings Inc. (IBP0) stockJuly 2025 Rallies & Daily Profit Focused Stock Screening - Улправда
Why analysts recommend Bio Path Holdings Inc. (IBP0) stock2025 Short Interest & Weekly Breakout Watchlists - Улправда
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Armistice Capital LLC Trims Holdings in UiPath, Inc. $PATH - Defense World
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Critical Survey: NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Bio-Path (NASDAQ:BPTH) - Defense World
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
P 500 performance this yearInflation Watch & Technical Pattern Alert System - Newser
Can Bio Path Holdings Inc. (IBP0) stock retain market dominanceJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears - GlobeNewswire
What consensus target says about Bio Path Holdings Inc. (IBP0) stockJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Analyzing Aadi Bioscience (NASDAQ:AADI) & Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path reports positive trial outcomes for cancer treatments - MSN
RNA Interference Pipeline Insights Report 2025: DelveInsight Highlights Emerging Therapeutics Transforming the Future Treatment Landscape - Barchart.com
Axos Financial loses $15M indemnification fight after merger trading fiasco - InvestmentNews
Bio-Path Holdings Inc. (BPTH) Stock Price | Live Quotes & Charts | PINL - StocksToTrade
MSN Money - MSN
North American Morning Briefing : Stock Futures Mostly Lower, AI Volatility Persists -2- - MarketScreener
Bio-Path Holdings Delays 10-Q Filing - MSN
Why ETFs are accumulating Bio Path Holdings Inc. (IBP0) stockTrade Volume Summary & Safe Entry Zone Tips - newser.com
Will Bio Path Holdings Inc. (IBP0) stock benefit from infrastructure billJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Bio Path Holdings Inc. (IBP0) stock a fit for income portfoliosTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Will Bio Path Holdings Inc. (IBP0) stock rise with strong economyRisk Management & Long Hold Capital Preservation Tips - newser.com
Bio-Path Holdings Seeks Financing for Strategic Turnaround - The Globe and Mail
Bio-Path Holdings announces board resignation and outlines turnaround plans - Investing.com Nigeria
Small Interfering RNA (siRNA) Therapeutics Market Future Trends and Scope Analysis Report - openPR.com
North American Morning Briefing : Futures Fall as Sentiment Weighed by Uncertainties -2- - MarketScreener
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.23%
Cap:
|
Volume (24h):